By PG In NewsPosted May 20, 2020 Sentien CEO Brian Miller Interviewed About Pursuing SBI-101 Treatment for COVID-19 Patients Read More
By PG In NewsPosted May 12, 2020 Sentien to Present SBI-101 Clinical Data in AKI at 2020 ASGCT Annual Meeting that Supports Expansion to COVID-19 Read More
By PG In NewsPosted October 2, 2019 Sentien CEO Brian Miller Presents at 2019 Cell & Gene Therapy Meeting on the Mesa Read More
By jguettler In NewsPosted May 16, 2018 Sentien Co-Founder Dr. Biju Parekkadan Gives a Live Interview at World Advanced Therapies & Regenerative Medicine Congress Read More
By jguettler In NewsPosted December 18, 2017 Sentien Co-Founder Dr. Biju Parekkadan Gives TEDx Talk at Rutgers University Read More
By jguettler In NewsPosted October 4, 2017 Sentien CEO Brian Miller Presents at Cell & Gene Therapy Meeting on the Mesa Read More
By jguettler In NewsPosted September 13, 2017 Cell Trials Data Selects Sentien’s Ph 1/2 Study of SBI-101 for AKI as Its Featured Advanced Cell Therapy Trial Read More
By jguettler In NewsPosted June 8, 2017 Sentien Announces Open Enrollment in Phase 1/2 Trial of SBI-101 for Patients with Acute Kidney Injury Read More
By jguettler In NewsPosted April 18, 2017 Sentien Biotechnologies Featured in FierceBiotech Read More
By jguettler In NewsPosted April 10, 2017 Sentien Announces Active IND for SBI-101 in Patients with Acute Kidney Injury At the Stem Cell Summit on 4/7, Sentien CEO Brian Miller announced that the company’s investigational new drug (IND) application for SBI-101 for the treatment of adult patients with acute [...] Read More
